The present invention relates to * combinations of: - component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or - stereoisomer thereof； - component B : one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof； - in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. - dependently of one another by the oral, intravenous, topical, local installations, - intraperitoneal or nasal route； * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer； * a kit comprising such a combination； * use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based dosage to increase sensitivity and/or to overcome resistance； * a method of determining the loss of tumor suppressor PTEN or FBXW7； and a method for determining perturbations in PIK3CA, PIK3CB, PIK3CD, PIK3CG, PI K3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and/or FGFR4.
